0001209191-22-060975.txt : 20221213 0001209191-22-060975.hdr.sgml : 20221213 20221213170631 ACCESSION NUMBER: 0001209191-22-060975 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221209 FILED AS OF DATE: 20221213 DATE AS OF CHANGE: 20221213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scalzo Richard William CENTRAL INDEX KEY: 0001789545 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 221460376 MAIL ADDRESS: STREET 1: 25 ALBERTA LANE CITY: HOLLISTON STATE: MA ZIP: 01746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-09 0 0001818794 Dyne Therapeutics, Inc. DYN 0001789545 Scalzo Richard William C/O DYNE THERAPEUTICS, INC. 1560 TRAPELO ROAD WALTHAM MA 02451 0 1 0 0 See Remarks Common Stock 2022-12-09 4 A 0 31000 0.00 A 56495 D Common Stock 2022-12-12 4 S 0 312 10.87 D 56183 D Stock Option (right to buy) 10.72 2022-12-09 4 A 0 45000 0.00 A 2032-12-08 Common Stock 45000 45000 D Consists of shares of Common Stock issuable under 31,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023. Includes 50,300 unvested RSUs. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Includes 49,257 unvested RSUs. This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026. Senior Vice President of Finance and Administration and Treasurer /s/ Richard Scalzo 2022-12-13